[
    [
        {
            "time": "",
            "original_text": "贝达药业：股东凯铭投资解除质押239万股",
            "features": {
                "keywords": [
                    "贝达药业",
                    "凯铭投资",
                    "解除质押",
                    "239万股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业：股东凯铭投资解除质押239万股",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：股东凯铭投资质押延期购回511万股",
            "features": {
                "keywords": [
                    "贝达药业",
                    "凯铭投资",
                    "质押延期",
                    "511万股"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业：股东凯铭投资质押延期购回511万股",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业(300558.SZ)：凯铭投资解押239万股及质押的511万股延期购回",
            "features": {
                "keywords": [
                    "贝达药业",
                    "凯铭投资",
                    "解押",
                    "239万股",
                    "质押延期",
                    "511万股"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)：凯铭投资解押239万股及质押的511万股延期购回",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "如何解决医药原始创新能力不足？强化基础研究成关键",
            "features": {
                "keywords": [
                    "医药",
                    "原始创新",
                    "基础研究"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "如何解决医药原始创新能力不足？强化基础研究成关键",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 4,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]